LONDON, UK / ACCESSWIRE / August 10, 2020 / Hutchison China MediTech (NASDAQ:HCM) continues to move swiftly towards its goal of globalization of its innovative oncology assets and building a fully integrated oncology business in China. Regarding the latter, the amended deal terms with Eli Lilly on fruquintinib is a huge positive, which will enable HCM to fully leverage its existing China oncology sales and marketing infrastructure across two assets: Elunate for CRC and surufatinib for NET. The recently reported interim results highlight further progress made since our recent outlook note. HCM is well funded (~$500m in available cash resources includes $119m unused debt facilities) as it accelerates the global development of its unpartnered assets and expands its China and global commercial outreach. Beyond 2024 we expect sustainable profitability and margin expansion. We value HCM at $6.69bn.
We value HCM at $6.69bn ($47.05/ADS) vs $6.3bn ($44.49/ADS) previously. The main driver of the uplift is the impact of Elunate deal terms to capture 70-80% of product value vs the prior 15-25% royalties on sales. Our valuation reflects net cash of $254m at end June 2020 plus ~$100m proceeds from the post-period private investment in public equity (PIPE) from General Atlantic. For full details, see our outlook note Eye of the tiger.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dr Susie Jana, +44 (0)20 3077 5700
Dr John Priestner, +44 (0)20 3077 5700
healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/600968/Edison-issues-ADR-update-on-Hutchison-China-MediTech-HCM
